Symbol="ATRA"
AssetType="Common Stock"
Name="Atara Biotherapeutics Inc"
Description="Atara Biotherapeutics, Inc., a commercially available T-cell immunotherapy company, develops treatments for cancer patients, autoimmune and viral diseases in the United States. The company is headquartered in South San Francisco, California."
CIK="1604464"
Exchange="NASDAQ"
Currency="USD"
Country="USA"
Sector="LIFE SCIENCES"
Industry="BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)"
Address="611 GATEWAY BLVD, SUITE 900, SOUTH SAN FRANCISCO, CA, US"
FiscalYearEnd="December"
LatestQuarter="2023-06-30"
MarketCapitalization="155286000"
EBITDA="-295590016"
PERatio="None"
PEGRatio="0"
BookValue="0.074"
DividendPerShare="0"
DividendYield="0"
EPS="-1.97"
RevenuePerShareTTM="0.066"
ProfitMargin="0"
OperatingMarginTTM="-43.8"
ReturnOnAssetsTTM="-0.551"
ReturnOnEquityTTM="-2.299"
RevenueTTM="6863000"
GrossProfitTTM="63573000"
DilutedEPSTTM="-1.97"
QuarterlyEarningsGrowthYOY="0"
QuarterlyRevenueGrowthYOY="-0.981"
AnalystTargetPrice="14.82"
TrailingPE="-"
ForwardPE="-"
PriceToSalesRatioTTM="4.538"
PriceToBookRatio="1.967"
EVToRevenue="2.31"
EVToEBITDA="-0.562"
Beta="0.991"
num_52WeekHigh="5.64"
num_52WeekLow="1.45"
num_50DayMovingAverage="1.944"
num_200DayMovingAverage="3.132"
SharesOutstanding="97972000"
DividendDate="None"
ExDividendDate="None"
symbol="ATRA"
open="1.56"
high="1.62"
low="1.49"
price="1.49"
volume="1008426.00"
latest_trading_day="2023-08-18"
previous_close="1.60"
change="-0.11"
change_percent="-6.8750%"
aroon_positive_momentum_days="10"
aroon_negative_momentum_days="0"
trend_strength="Absent or Weak Trend"
buying_signal="Strong Buy Signal"
volume_analysis="Target Volume"
value_analysis="Expected Range"
Aroon_change="FALSE"
Aroon_momentum="10"
Volume_recent_avg="1656736"
Change_recent_avg="-0.01"
Delta_recent_avg="0.2"
Variance_recent_avg="0.1"
Change_ratio_recent_avg="-0.89"
RSI_change="FALSE"
ADX_change="FALSE"

event="aroon_milestone_positive_10"
Aroon_signal="positive"
Aroon_change="FALSE"
Aroon_momentum_positive="10"
Aroon_momentum_negative="90"
image_negative_thumbnail_id_1="1119"
image_negative_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Negative_Landscape_0152.jpeg"
image_negative_thumbnail_id_2="1165"
image_negative_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Negative_Landscape_0199.jpeg"
image_neutral_thumbnail_id_1="539"
image_neutral_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0060.jpeg"
image_neutral_thumbnail_id_2="584"
image_neutral_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0015.jpeg"
image_positive_thumbnail_id_1="628"
image_positive_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0080.jpeg"
image_positive_thumbnail_id_2="663"
image_positive_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0045.jpeg"
image_professor_thumbnail_id_1="1196"
image_professor_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0030.jpeg"
image_professor_thumbnail_id_2="1185"
image_professor_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0019.jpeg"
